Objective-Plasminogen activator inhibitor-1 (PAI-1) regulates angiogenesis via effects on extracellular matrix proteolysis and cell adhesion. However, no previous study has implicated PAI-1 in controlling vascular endothelial growth factor (VEGF) signaling. We tested the hypothesis that PAI-1 downregulates VEGF receptor-2 (VEGFR-2) activation by inhibiting a vitronectin-dependent cooperative binding interaction between VEGFR-2 and α V β 3 . Approach and Results-We studied effects of PAI-1 on VEGF signaling in human umbilical vein endothelial cells. PAI-1 inhibited VEGF-induced phosphorylation of VEGFR-2 in human umbilical vein endothelial cells grown on vitronectin, but not on fibronectin or collagen. PAI-1 inhibited the binding of VEGFR-2 to β 3 integrin, VEGFR-2 endocytosis, and intracellular signaling pathways downstream of VEGFR-2. The anti-VEGF effect of PAI-1 was mediated by 2 distinct pathways, one requiring binding to vitronectin and another requiring binding to very low-density lipoprotein receptor. PAI-1 inhibited VEGF-induced angiogenesis in vitro and in vivo, and pharmacological inhibition of PAI-1 promoted collateral arteriole development and recovery of hindlimb perfusion after femoral artery interruption.
A ngiogenesis is an intensely regulated process that is integral to the evolution of many human diseases, including ischemic cardiovascular disease and cancer metastasis. Several studies have implicated plasminogen activator inhibitor-1 (PAI-1), the primary endogenous inhibitor of tissue-type plasminogen activator, and urinary-type plasminogen activator (uPA), as playing an important role in regulating angiogenesis. PAI-1 exerts both proangiogenic and antiangiogenic properties, with the concentration of PAI-1 being an important determinant of which effect is observed. 1, 2 The proangiogenic effect of PAI-1 seems to be mediated by stabilizing the extracellular matrix (ECM) through inhibition of proteolysis 2, 3 and by stimulation of fibronectin-dependent cell migration. 4 The antiangiogenic effect of PAI-1 seems to be mediated by binding of PAI-1 to vitronectin, 5 an ECM protein that promotes cell adhesion and migration by binding to cell surface receptors, including α V β 3 integrin, and to the uPA receptor (uPAR). The binding site for PAI-1 on vitronectin overlaps with vitronectin's binding sites for α V β 3 and uPAR. Therefore, binding of PAI-1 to vitronectin blocks cell adhesion and migration, and hence, inhibits angiogenesis. 6 Although PAI-1 regulates angiogenesis through downstream effects on ECM proteolysis and cell migration, no studies have implicated PAI-1 in controlling upstream signaling pathways that initiate angiogenesis. Critical among these is the activation of endothelial cells, mediated by binding of a vascular endothelial growth factor (VEGF) to its main angiogenic receptor, VEGF receptor-2 (VEGFR-2). 7 A cooperative binding interaction between VEGFR-2 and α V β 3 integrin plays a key role in regulating VEGF signaling in endothelial cells. 8 This receptor cross talk depends on binding of α V β 3 to vitronectin. 9, 10 Given that PAI-1 regulates binding of α V β 3 to vitronectin, we hypothesized that PAI-1 regulates VEGF-mediated endothelial cell activation by disrupting VEGFR-2-α V β 3 cross talk. In this study, we performed a series of biochemical, cell culture, and in vivo experiments to test our hypothesis. Our results identify a previously unrecognized role of PAI-1 in regulating VEGF signaling, which is vitronectin-dependent and mediated by 2 distinct PAI-1 ligands.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

PAI-1 Blocks VEGFR-2-β 3 Integrin Complex Formation
Vitronectin is a major ligand for α v β 3 , and it significantly enhances VEGF-mediated activation of endothelial cells via VEGFR-2. 10, 11 Given that PAI-1 binds to vitronectin and blocks its binding to α v β 3 , 6 we hypothesized that PAI-1 inhibits the vitronectin-dependent binding interaction between α v β 3 and VEGFR-2. To test this hypothesis, we cultured human umbilical vein endothelial cells (HUVECs) in vitronectincoated wells and prepared cell extracts before and after treating cells with the VEGF in the absence or in the presence of PAI-1-wild-type (WT). VEGFR-2-α v β 3 complexes in extracts were captured with an immobilized anti-VEGFR-2 antibody and detected by Western blotting with an anti-β 3 integrin antibody. Coimmunoprecipitation of β 3 integrin and VEGFR-2 was significantly enhanced by VEGF and inhibited by PAI-1-WT ( Figure 1A ), suggesting that VEGF induces VEGFR-2-α v β 3 complex formation and PAI-1 inhibits this process.
PAI-1 Inhibits VEGFR-2 Phosphorylation, Internalization, and Signaling
To determine whether PAI-1 inhibits VEGF-induced VEGFR-2 activation, we cultured HUVECs in wells coated with collagen, fibronectin, or vitronectin in the presence of PAI-1-WT or vehicle control. After 4 hours, VEGF or vehicle control was added for 10 minutes, after which cell lysates were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting. VEGF stimulated a significant increase in VEGFR-2 phosphorylation in HUVECs, regardless of whether they were cultured on collagen, fibronectin, or vitronectin although the magnitude of enhancement was the greatest for cells grown on vitronectin ( Figure 1B) . The stimulatory effect of VEGF on VEGFR-2 phosphorylation was inhibited by PAI-1-WT in HUVECs cultured on vitronectin. However, PAI-1-WT had no significant effect on VEGFR-2 phosphorylation in HUVECs grown on collagen or fibronectin. The inhibitory effect of PAI-1-WT on VEGFR-2 phosphorylation was dose dependent ( Figure I in the online-only Data Supplement). The latent form of PAI-1, which has no protease inhibitory activity and binds to vitronectin with markedly reduced affinity, had no significant effect on VEGFR-2 phosphorylation, including in HUVECs cultured on vitronectin (data not shown). PAI-1-WT neither bind to recombinant VEGF nor inhibit binding of VEGF to recombinant VEGFR-2 ( Figure II in the online-only Data Supplement). We did not observe any significant detachment of HUVECs from wells in response to PAI-1 treatment (data not shown). As a whole, these results suggested that PAI-1 inhibits VEGF-induced VEGFR-2 activation by a vitronectin-dependent mechanism.
After engagement by VEGF, VEGFR-2 undergoes endocytosis, which plays an important role in VEGFR-2 signaling. 12, 13 PAI-1-WT significantly inhibited the internalization of biotinylated VEGFR-2 by HUVECs ( Figure 1C ). To define the effect of PAI-1 on VEGFR-2 internalization better, HUVECs were cultured in vitronectin-coated wells and treated with PAI-1-WT or vehicle control, after which VEGF was added and cellular localization of VEGFR-2 was assessed by immunofluorescence. Consistent with a previous report, 14 VEGF stimulated translocation of VEGFR-2 to perinuclear endosomes. PAI-1-WT significantly inhibited the perinuclear transfer of VEGFR-2 ( Figure 1D ). We also examined the effect of PAI-1-WT on intracellular signaling pathways activated by binding of VEGF to VEGFR-2. PAI-1-WT inhibited VEGF-induced phosphorylation of focal adhesion kinase and p44/42 mitogenactivated protein kinases (1E). PAI-1-WT also inhibited VEGFinduced coimmunoprecipitation of VEGFR-2 and β 3 integrin, and phosphorylation of both VEGFR-2 and p44/p42 in human microvascular endothelial cells ( Figure III in the online-only Data Supplement), confirming that the anti-VEGF effect of PAI-1 was not restricted to HUVECs. As a whole, these experiments suggested that PAI-1 inhibits VEGFR-2 internalization and downstream signaling in vascular endothelial cells.
Inhibition of VEGF Signaling by PAI-1 Depends on Vitronectin and Low-Density Lipoprotein Receptor Family Member Binding
To determine which of functional interactions of PAI-1 mediate its effects on VEGFR-2 activation, we studied the capacity of recombinant PAI-1 proteins harboring specific loss-of-function mutations to inhibit VEGFR-2 phosphorylation. We performed these experiments with HUVECs whose endogenous PAI-1 expression was silenced with PAI-1 siRNA. This approach decreased PAI-1 expression by ≈80% ( Figure 2A ). Under these conditions, PAI-1-WT efficiently inhibited VEGFR-2 phosphorylation, as did PAI-1-R, a mutant with preserved vitronectin binding, but lacking antiprotease activity ( Figure 2B ). These results suggested that the antiprotease activity of PAI-1 was not absolutely required to inhibit VEGFR-2 activation and supported the hypothesis that PAI-1 inhibits VEGF signaling by a mechanism involving the PAI-1-vitronectin binding domain. Unexpectedly, PAI-1-AK, which retains full antiprotease activity, but does not bind to vitronectin, also inhibited VEGF-induced VEGFR-2 phosphorylation ( Figure 2B ). This result suggested that the PAI-1-vitronectin binding interaction was sufficient, but not required, for PAI-1 to inhibit VEGFR-2 signaling. It also suggested that although PAI-1-mediated downregulation of VEGF signaling was vitronectin-dependent, direct binding of PAI-1 to vitronectin was not absolutely required to exert this effect. In addition to a vitronectin binding site, PAI-1 contains a cryptic binding site for low-density lipoprotein (LDL) receptor-related protein 1 and related endocytic receptors of the LDL receptor family, which becomes exposed after PAI-1 binds to uPA. 15 We hypothesized that binding of PAI-1 to an endocytic receptor inhibits VEGFR-2 activation by VEGF beacuse endocytic receptor binding capacity is retained in PAI-1-AK. 16 Therefore, we studied the capacity of PAI-1-E, a mutant with markedly reduced binding capacity for LDL receptor family members, 15 to inhibit VEGF-induced VEGFR-2 phosphorylation. PAI-E inhibited VEGF-induced VEGFR-2 phosphorylation ( Figure 2B ). However, because the inhibitory effect of PAI-1-E could be mediated by its retained capacity to bind to vitronectin, we also constructed a compound mutant, PAI-1-AKE, which contained all of the mutations in PAI-1-AK and PAI-1-E. PAI-1-AKE retains full antiprotease activity, but does not bind to vitronectin or LDL receptor family members with high-affinity. Unlike PAI-1-AK and PAI-1-E, PAI-1-AKE did not significantly inhibit VEGFinduced VEGFR-2 phosphorylation ( Figure 2B ) HUVECs were cultured on VN, collagen, or fibronectin in the presence of vehicle control, VEGF (50 ng/mL), VEGF, and PAI-1-WT (10 μg/mL), or PAI-1-WT, as indicated. Cell lysates were prepared and subjected to Western blotting to detect phosphorylated (p) and total VEGFR-2. C, PAI-1 inhibits VEGFR-2 endocytosis. HUVEC surface proteins were biotinylated, after which cells were cultured in the presence of vehicle control, VEGF, or VEGF and PAI-1-WT, as shown. Internalized VEGFR-2 was detected by Western blotting. D, PAI-1 inhibits translocation of VEGFR-2 to perinuclear endosomes. HUVECs were cultured on VN in the presence of vehicle control, VEGF (50 ng/mL), VEGF, and PAI-1-WT (10 μg/mL), or PAI-1-WT, as indicated. VEGFR-2 and early endosome antigen 1 (EEA1) were detected by immunofluorescence confocal microscopy. 4′,6-Diamidino-2-phenylindole (DAPI) (nuclear) and merged VEGFR-2/EEA1/DAPI images are also shown. Images are representative of 3 independent experiments. Arrows indicate perinuclear location of VEGFR-2. E, PAI-1 inhibits intracellular signaling pathways downstream of VEGFR-2. HUVECs were cultured on VN in the presence of vehicle control, VEGF, or VEGF and PAI-1-WT, as indicated. Cell lysates were prepared and subjected to Western blotting to detect phosphorylated, and total focal adhesion kinase (FAK) and p44/p42. All graphs correspond to the blots above them and represent densitometric analyses of 3 independent experiments. *P<0.05 vs negative control group (first bar).
blocks binding of PAI-1 to LDL receptor-related protein 1 and other LDL receptor family members, 17 completely inhibited the capacity of PAI-1-AK to downregulate VEGFR-2 phosphorylation ( Figure 2C ). As a whole, these findings suggested that PAI-1 binding to either vitronectin or an endocytic receptor was sufficient to inhibit VEGFR-2 signaling. We also studied the capacity of PAI-AK to inhibit VEGFR-2 phosphorylation in the presence of a synthetic peptide, D2A-Ala, which blocks binding of uPAR to α V β 3 . 18 D2A-Ala potently inhibited the capacity of PAI-1-AK to disrupt VEGFR-2 activation, whereas a control (scrambled) peptide had no significant effect ( Figure IV in the online-only Data Supplement), suggesting that PAI-1 binding to an endocytic receptor family member inhibits VEGFR-2 signaling by a pathway involving a uPAR-integrin binding interaction.
PAI-1 Inhibits VEGF-Induced Endothelial Cell Adhesion, Migration, and Cord Formation in a Vitronectin-Dependent Manner
We examined the effects of PAI-1 on the physiological responses of endothelial cells to VEGF stimulation. In the absence of added PAI-1, VEGF significantly stimulated adhesion and migration of HUVECs grown on vitronectin, collagen, or fibronectin ( Figure 3A and 3B, white bars), with the stimulatory effect being maximal in cells grown on vitronectin. In the absence of added VEGF, PAI-1-WT and PAI-1-R each significantly inhibited, but did not completely block, adhesion and migration of HUVECs cultured in vitronectincoated wells, whereas PAI-1-AK had no significant effect, consistent with its defect in vitronectin binding. However, PAI-1-AK completely inhibited the upregulation of adhesion and migration induced by VEGF in HUVECs cultured on vitronectin, as did PAI-1-WT and PAI-1-R. PAI-1-WT, PAI-1-R, and PAI-1-AK had no significant effect on adhesion or migration of HUVECs cultured on fibronectin or collagen, either in the presence or in the absence of added VEGF. VEGF stimulates cultured endothelial cells to form cordlike structures that mimic forming blood vessels. To examine the effect of PAI-1 on this process, HUVECs were cultured on Matrigel formed in the presence or in the absence of supplemental vitronectin. PAI-1-WT inhibited the augmentation of tubule formation by VEGF in vitronectin-supplemented Matrigel, but not in Matrigel-lacking supplemental vitronectin ( Figure 3C and 3D) .
To explore the functional significance of interactions of PAI-1 with vitronectin and endocytic receptor(s) in regulating VEGF signaling further, we studied the effects of recombinant PAI-1 mutants on VEGF-induced migration of vitronectin-adherent HUVECs in the presence and in the absence of RAP. In the absence of RAP, PAI-1-WT, PAI-1-R, and PAI-1-AK each inhibited VEGF-induced migration ( Figure VA in the online-only Data Supplement, bars 6-8). In the presence of RAP, PAI-1-WT and PAI-1-R each retained the capacity to inhibit VEGF-induced migration (bars 9-10), whereas the inhibitory effect of PAI-1 AK was lost (bar 11). Furthermore, in a separate set of experiments performed in the absence of RAP, PAI-1-AKE did not inhibit VEGF-induced HUVEC migration ( Figure VB in the online-only Data Supplement, bar 4), whereas PAI-1-E, which is defective in endocytic receptor binding, but retains normal vitronectin binding affinity, inhibited VEGFinduced HUVEC migration (bar 5). Together, these results supported the functional significance of PAI-1 binding to either vitronectin or an LDL receptor family member in regulating VEGF signaling. They also suggested that the endocytic-receptor-dependent role of PAI-1 in VEGF signaling although not requiring binding of PAI-1 to vitronectin, still exhibited vitronectin-dependence because the effect of PAI-1-WT, which binds to LDL receptor-related protein 1 and other LDL receptor family members, was lost in the absence of vitronectin.
Binding of PAI-1 to Very Low-Density Lipoprotein Receptor Inhibits VEGF Signaling
Becasue the very LDL receptor (VLDLR) is thought to be the primary LDL receptor family member present on HUVECs, 19, 20 we examined whether the ability of PAI-1-AK to inhibit VEGF-induced cell migration could be reversed by an antibody that specifically blocks ligand binding to VLDLR. These studies demonstrated that the VLDLR antibody completely inhibited the anti-VEGF effect of PAI-1-AK ( Figure  VC 
VEGF-Induction of Angiogenesis Ex Vivo and In Vivo is Vitronectin-Dependent and Inhibited by PAI-1
To examine the role of vitronectin in VEGF-induced angiogenesis under physiological conditions, we cultured segments of aorta from WT and Vn −/− mice ex vivo in Matrigel in the presence or in the absence of VEGF. The capacity of VEGF to stimulate microvessel sprouting was significantly greater in WT mice than in Vn −/− mice ( Figure 4A and 4B) . Immunostaining confirmed the presence of vitronectin in aorta of WT mice ( Figure VIA in the online-only Data Supplement). PAI-1-WT significantly inhibited VEGF-induced microvessel sprouting from WT aorta; however, PAI-1-AKE had no significant effect ( Figure 4C ). To study the significance of our findings in vivo, we injected VEGF-impregnated Matrigel into subcutaneous tissue of WT and Vn −/− mice. After 14 days, solidified gels were retrieved, and blood vessel invasion into them was measured. VEGF significantly increased endothelial cell invasion into Matrigels in WT mice, but not in Vn −/− mice ( Figure 4D and 4E). Immunostaining confirmed that host-derived vitronectin diffused into Matrigel implants ( Figure VIB in the onlineonly Data Supplement). To determine whether PAI-1 inhibits VEGF-induced angiogenesis in vivo, we injected Matrigel supplemented with PAI-1-WT (10 μg/mL) into WT and Vn −/− mice. PAI-1-WT completely inhibited VEGF-induced angiogenesis in WT mice, but had no significant effect in Vn −/− mice ( Figure 4D and 4E) . These results suggested that PAI-1 and vitronectin play key roles in regulating VEGF-induced angiogenesis in vivo, and that PAI-1 could be used to inhibit VEGF-induced angiogenesis pharmacologically. However, downregulation of fibrinolysis by active PAI-1 could promote thrombosis. Given that PAI-1-R does not inhibit plasminogen activators, we tested its capacity to inhibit VEGF-induced angiogenesis in vivo in WT mice. PAI-1-R significantly inhibited VEGF-induced angiogenesis (Figure 4F and 4G) . 
Pharmacological Inhibition of PAI-1 Promotes Reperfusion of Ischemic Hindlimb Tissue
To examine the significance of our findings in a pathological model of PAI-1 overexpression relevant to human cardiovascular disease, we fed mice high-fat chow for 14 weeks, which produced obesity, hyperglycemia, and a significant increase in plasma PAI-1 concentration ( Figure VII in the online-only Data Supplement). Hindlimb ischemia was induced in high-fat chow-fed mice by ligation and excision of the femoral artery, after which mice received PAI-039, a specific PAI-1 inhibitor, or vehicle control. After 14 days of treatment, plasma PAI-1 activity was significantly lower in PAI-039-treated mice (0.61±0.09 ng/mL) than in controls (2.66±0.35 ng/mL; P<0.05; n=6 per group). Laser Doppler imaging revealed that the recovery of perfusion of ischemic hindlimb tissue after femoral artery interruption was significantly increased in PAI-039-treated mice compared with vehicle controls (Figure 5A and 5B) . Consistent with these results, arteriole density in ischemic gastrocnemius muscle 14 days after induction of ischemia was significantly increased in PAI-039-treated mice versus controls ( Fig. 5C  and 5D ). Capillary density in ischemic gastrocnemius muscle did not differ significantly between experimental groups ( Figure 5E ).
Discussion
We describe a previously unrecognized role of PAI-1 in regulating VEGF-induced activation of its main angiogenic receptor, VEGFR-2. Specifically, PAI-1 inhibits VEGFR-2 phosphorylation and translocation to perinuclear endosomes, as well as intracellular signaling downstream of VEGFR-2. The antiprotease function of PAI-1 is not absolutely required for it to inhibit VEGFR-2 activation because PAI-1-R, a mutant devoid of antiprotease activity, inhibited VEGF signaling. This observation is consistent with the high-affinity binding interaction between PAI-1 and vitronectin, which inhibits binding of vitronectin to its cell surface receptors. 6 Our data suggest that the antiangiogenic property of PAI-1-R is mediated by its capacity to competitively inhibit binding of α V β 3 integrin to vitronectin. However, an intriguing aspect of our study is the observation that inhibition of VEGFR-2 activation and angiogenic signaling by PAI-1, while requiring vitronectin, is not mediated solely by binding to vitronectin, as evidenced by the preserved antiangiogenic effect of PAI-1-AK, which has no measurable vitronectin binding affinity. Experiments examining how PAI-1 can inhibit VEGF signaling in a vitronectin-dependent manner without binding vitronectin led us to uncover another previously unrecognized regulator of VEGFR-2 activation, which seems to be the VLDLR. This conclusion is supported by 3 lines of evidence. First, the antiangiogenic activity of PAI-1-AK is inhibited by RAP, an antagonist of LDL receptor family members; second, the antiangiogenic activity of PAI-1-AK is lost on introduction of an additional glutamate mutation (PAI-1-AKE) that ablates the capacity of PAI-1to bind to LDL receptor family members; and third, the ability of PAI-1-AK to inhibit VEGF-induced HUVEC migration is blocked by an antibody directed against the ligand binding repeats of VLDLR. These results suggest that VLDLR, which is expressed by endothelial cells, 19, 20 is the LDL receptor family member that mediates theantiangiogenic effect of PAI-1 and is consistent with a study showing that VLDLR signaling exerts an antiangiogenic effect on retinal endothelial cells. 21 On the basis of our data and published studies, we hypothesize that α v β 3 integrin and its ligand, vitronectin, underpin the capacity of PAI-1 to inhibit VEGFR-2 activation, whether by binding to vitronectin or VLDLR, as illustrated in Figure 6 . Previous studies showed that α v β 3 and vitronectin potently enhance VEGFR-2 activation by VEGF, 9, 10 demonstrating a key role of α v β 3 -VEGFR-2 cross talk in VEGF signaling and the vitronectin-dependent nature of this interaction ( Figure 6A ). By binding to the somatomedin B domain of vitronectin, PAI-1 competitively inhibits binding of α v β 3 to the vitronectin's immediate adjacent integrin binding site. 6 Our experiments involving recombinant PAI-1 mutants suggest that blockade of the α v β 3 -vitronectin binding interaction by binding of PAI-1 to vitronectin directly uncouples α v β 3 -VEGFR-2 cross talk and downregulates VEGFR-2 activation ( Figure 6B ). Alternatively, binding of PAI-1 to VLDLR (most likely in the form of PAI-1-uPA complex) 15, 22 has the potential to uncouple α v β 3 from VEGFR-2 indirectly because it has been shown that the PAI-1-uPA complex also binds to uPAR, which itself binds to integrins and regulates their adhesive and signaling properties. 23 Specifically, formation of a macromolecular complex consisting of VLDLR, PAI-1, uPA, uPAR, and α V β 3 (or other integrins) can lead to integrin inactivation and disengagement from the ECM. 24, 25 Disengagement of α V β 3 from vitronectin by this pathway would be anticipated to inhibit the vitronectin-dependent cross talk between α V β 3 and VEGFR-2, thereby downregulating VEGF signaling ( Figure 6C ). Our data suggest that binding of PAI-1 to VLDLR is required for PAI-1 to dissociate C A VLDLR B VLDLR VLDLR Figure 6 . Proposed model by which plasminogen activator inhibitor-1 (PAI-1) inhibits vascular endothelial growth factor (VEGF) signaling. A, VEGF induces strong angiogenic signaling (large intracellular arrow) when α V β 3 is bound to vitronectin (VN) and VEGF receptor-2 (VEGFR-2). B, PAI-1 binds to VN and competitively blocks binding of α V β 3 , which uncouples the proangiogenic binding interaction between α V β 3 and VEGFR-2 and downregulates VEGF signaling (small intracellular arrow). C, PAI-1-urinary-type plasminogen activator (uPA) complex binds to the very low-density lipoprotein receptor (VLDLR) and uPA receptor (uPAR), which, through a uPAR-α V β 3 binding interaction, triggers dissociation of α V β 3 from VN, thereby uncoupling the proangiogenic binding interaction between α V β 3 and VEGFR-2, which downregulates VEGF signaling.
α v β 3 from vitronectin functionally via the pathway that does not require direct PAI-1 binding to vitronectin, because the antiangiogenic effect of PAI-1-AK (which does not bind to vitronectin, but binds to the uPA-uPAR complex) was lost on introduction of an additional mutation into PAI-1-AK that ablated LDL receptor family member binding. The VLDLRdependent antiangiogenic effect of PAI-1 could be mediated by endocytic-receptor-mediated internalization of α v β 3 (along with PAI-1, uPA, and uPAR, as has been described) 24, 26 or by conformational changes in α V β 3 that are not accompanied by its cellular internalization. 25 This issue was not resolved by our experiments. However, we showed that peptide-mediated inhibition of uPAR-integrin binding potently inhibited the anti-VEGF effect of PAI-1-AK, suggesting that PAI-1 disrupts VEGF signaling by a pathway involving uPAR-integrin complex formation. Consistent with our results, Alexander et al 27 showed that uPAR is an important determinant of VEGF signaling in endothelial cells. Additional studies are necessary to define the molecular events underlying the VLDLRdependent downregulation of VEGFR-2 signaling by PAI-1 more precisely.
Our experiments involving microvessel sprouting from aortic rings ex vivo and microvessel invasion into subcutaneous ECM implants in vivo suggest that PAI-1 is a physiologically relevant regulator of VEGFR-2 activation. On the basis of our data, we hypothesize that enhanced PAI-1 expression, which occurs under pathological conditions, such as diabetes mellitus, 28 inhibits VEGFR-2 activation in vivo. Consistent with this hypothesis, we showed that PAI-039, a highly specific pharmacological inhibitor of PAI-1 with no discernable effect on angiogenesis in PAI-1-deficient mice, 29, 30 promoted the recovery of tissue perfusion and development of collateral arterioles after induction of hindlimb ischemia in mice with diet-induced PAI-1 overexpression. Previous studies have shown that collateral arteriole development and recovery of tissue perfusion after femoral artery occlusion are dependent on VEGFR-2 activation by VEGF. 31, 32 Therefore, our findings with PAI-039 and another murine study involving pharmacological PAI-1 inhibition 33 support the in vivo relevance of the inhibition of VEGFR-2 activation by PAI-1. We did not observe an increase in capillary density in ischemic gastrocnemius muscle in response to PAI-039 treatment. However, this does not rule out an effect of PAI-1 on capillary remodeling. Furthermore, the dominant determinant of tissue reperfusion after femoral artery ligation is collateral arteriole development, 34 and we observed a positive effect of PAI-039 on this angiogenic response. A limitation of our hindlimb ischemia model experiment is that we cannot definitively conclude that pharmacological inhibition of PAI-1 promoted tissue reperfusion solely by blocking the negative effect of PAI-1 on VEGFR-2 activation, because pharmacological inhibition of PAI-1 could potentially modulate the angiogenic response to ischemia by VEGFR-2-independent pathways. Nevertheless, our hindlimb ischemia model data support the significance of our proposed molecular mechanisms in a clinically relevant, in vivo context, thereby complementing our cell culture, ex vivo aortic ring, and in vivo Matrigel plug data, which demonstrated that PAI-1 inhibits VEGFR-2 activation. Additional in vivo studies will be necessary to dissect further and characterize better the significance of our newly reported regulatory pathway on VEGF-dependent angiogenic signaling in normal vascular development and other disease models.
In summary, we have shown that PAI-1 inhibits VEGFR-2 activation by VEGF in a vitronectin-dependent manner. Our data suggest that PAI-1 mediates its effect by inhibiting binding of α V β 3 to its ECM ligand, vitronectin, thereby disrupting the proangiogenic binding interaction between α V β 3 and VEGFR-2. The antiangiogenic effect of PAI-1 seems to be mediated, although not exclusively, by direct binding to vitronectin, which competitively blocks binding of vitronectin to α V β 3 . We also have shown that binding of PAI-1 to an endocytic receptor of the LDL receptor family inhibits VEGFR-2 activation, and that this effect is inhibited by an antibody that blocks ligand binding to VLDLR. Our results suggest that VLDLR plays an important role in VEGF signaling, one which is sensitive to inhibition by PAI-1 and mediated by functional disengagement of α V β 3 from vitronectin. We have shown that the anti-VEGF effect of PAI-1 is evident under physiological conditions in vitro and in vivo. Overall, our results broaden our understanding of the roles of PAI-1, vitronectin, and the LDL receptor family in regulating angiogenic signaling. They also support proceeding to additional preclinical studies involving recombinant PAI-1 mutants and pharmacological PAI-1 inhibitors as therapeutic strategies to inhibit or promote angiogenesis in vivo.
